HIV-associated nephropathy

Focal Segmental Glomerulosclerosis (FSGS) Pipeline Insight Report 2020: Comprehensive Insights About 15+ Companies and 15+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 15, 2021

b'This segment of the Focal Segmental Glomerulosclerosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.

Key Points: 
  • b'This segment of the Focal Segmental Glomerulosclerosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
  • Retrophin is examining the ability of sparsentan to slow the decline of kidney function in patients with FSGS and IgAN.
  • It is a single molecule designed to be a dual endothelin receptor type A (ETA) and angiotensin II receptor type 1 (AT1) antagonist.
  • It is currently in phase II stage of development.\nDelta 4 is working on its lead program which aims at developing a therapy for Focal Segmental Glomerulosclerosis (FSGS).

DIMERIX’s DMX-200 Posts Strong Results in Kidney Disease Trial

Retrieved on: 
Wednesday, July 29, 2020

Melbourne-based, clinical-stage biopharmaceutical company Dimerix has reported excellent results from the clinical trial of its drug candidate DMX-200, which is aimed at a rare kidney disease called focal segmental glomerulosclerosis, or FSGS.

Key Points: 
  • Melbourne-based, clinical-stage biopharmaceutical company Dimerix has reported excellent results from the clinical trial of its drug candidate DMX-200, which is aimed at a rare kidney disease called focal segmental glomerulosclerosis, or FSGS.
  • FSGS is caused by scarring in the kidney, which can cause kidney damage and failure.
  • The disease attacks the tiny filtering units inside a persons kidney where blood is cleaned, known as glomeruli.
  • FSGS leads to permanent kidney damage and kidney failure in both adults and children as young as 2 years old.

Perlara announces APOL1 kidney disease PerlQuest partnership with Rambam Medical Center

Retrieved on: 
Thursday, December 27, 2018

SOUTH SAN FRANCISCO, Calif., Dec. 27, 2018 /PRNewswire/ --Perlara, the rare diseases platform company that partners with highly motivated families, organizations, researchers and impact investors to cure rare genetic diseases, today announced an APOL1 kidney disease PerlQuest co-development partnership with Rambam Medical Center in Haifa, Israel, and the laboratory of leading nephrologist and kidney disease researcher Dr. Karl Skorecki.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Dec. 27, 2018 /PRNewswire/ --Perlara, the rare diseases platform company that partners with highly motivated families, organizations, researchers and impact investors to cure rare genetic diseases, today announced an APOL1 kidney disease PerlQuest co-development partnership with Rambam Medical Center in Haifa, Israel, and the laboratory of leading nephrologist and kidney disease researcher Dr. Karl Skorecki.
  • APOL1 kidney disease is a group of nondiabetic chronic progressive kidney diseases which include forms of hypertension with reduced kidney function, Focal Segmental Glomerulosclerosis, lupus nephritis and HIV associated nephropathy.
  • Individuals with two risk variants are at a greatly increased risk for developing progressive kidney disease, often with urinary protein leakage.
  • Rambam Medical Center is a state medical institution housing 36 hospitalization departments, 45 medical and diagnostic units, 10 institutes, and 6 laboratories.

NephCure Kidney International's Annual Countdown to a Cure Gala in NYC on Track for Record-Breaking Year

Retrieved on: 
Thursday, November 1, 2018

FSGS is a rare and chronic kidney disease and the leading cause of kidney failure in children.

Key Points: 
  • FSGS is a rare and chronic kidney disease and the leading cause of kidney failure in children.
  • IgA Nephropathy is a leading cause of chronic kidney disease worldwide, with approximately half of all individuals eventually developing kidney failure.
  • NephCure has devoted the past two decades towards investing in essential kidney disease research and is now in the final phases of bringing new therapies to patients.
  • To date, the annual Countdown to a Cure gala has raised more than seven million dollars for NephCure to advance research into effective treatments for patients with Nephrotic Syndrome.